• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Risk of Stillbirth: Interaction Between Gestational Duration, Parity, and BMI

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Interactions between risk factors for stillbirth are not well characterized
  • Lindegren et al. (BJOG, 2021) investigated interactions between gestational age (≥39 weeks), BMI and parity on stillbirth or neonatal death

METHODS:

  • Retrospective study
  • Population
    • Singleton, cephalic births at gestational duration
    • 39w0d to 42w2d
  • Exposure
    • Parity
    • Maternal BMI
  • Study design
    • Relative risk ratios (RR) for mortality in relation to gestational duration were stratified by exposure
    • Relative RRs were adjusted for maternal age, smoking, country of birth, and educational level
  • Primary outcome
    • Stillbirth or neonatal death <45 post-menstrual weeks
  • Secondary outcome
    • Stillbirth

RESULTS:

  • 892,339 births
  • Among primiparous women, infants born at ≥41w3d were at increased risk of stillbirth or neonatal death before <45 post-menstrual weeks vs 39w0d to 40w2d
    • aRR 1.29 (95% CI, 1.10 to 1.52)
  • Primiparous women: Gestational age risk was modulated by BMI
    • BMI <25: aRR 1.04 (95% CI, 0.81 to 1.34)
    • BMI 25 to 29.9: aRR 1.25 (95% CI, 0.94 to 1.66)
    • BMI ≥30: aRR 1.52 (95% CI, 1.10 to 2.10)
  • Among primiparous women, the risk of stillbirth increased with gestational duration in all BMI strata, with the highest risk increase for BMI ≥30
    • At 40w3d to 40w6d: 0.8 of every 1000 births
    • At 42w0d to 42w2d: 4.0 of every 1000 births
  • Multiparous women: No significant increase in risk with increased gestational age, regardless of BMI

CONCLUSION:

  • Among primiparous women, pregnancies lasting more than 41w3d were at increased risk for stillbirth or neonatal death <45 weeks post-menstruation
    • This risk was higher in women with BMI ≥30
  • For multiparous women, there was no significant association with gestational duration and neonatal mortality
  • The authors state

The risk for stillbirth (our secondary outcome) in pregnancies at 39+0 weeks of gestation and beyond was more than doubled among primiparous compared with multiparous women

To our knowledge, no other study has been published that report fetal and neonatal deaths by BMI discretely for primiparous and multiparous women

Learn More – Primary Sources:

Stillbirth or neonatal death before 45 post-menstrual weeks in relation to gestational duration in pregnancies at 39 weeks or beyond: the impact of parity and body mass index. A national cohort study

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

More from MiNESS: Evidence that GDM Screening and Management May Prevent Late Term Stillbirth
Are Large-for-Gestational Age Pregnancies at an Increased Risk of Stillbirth?
Obesity and Stillbirth At Term – What is the Actual Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site